Lixisenatide as add‐on treatment among patients with different β‐cell function levels as assessed by HOMA‐β index

BACKGROUND: The effect of lixisenatide—a prandial once‐daily glucagon‐like peptide‐1 receptor agonist—on glycaemic control in patients with inadequately controlled type 2 diabetes mellitus (T2DM), stratified by baseline β‐cell function, was assessed. METHODS: The 24‐week GetGoal‐M, ‐P and ‐S trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonadonna, Riccardo C., Blonde, Lawrence, Antsiferov, Mikhail, Berria, Rachele, Gourdy, Pierre, Hatunic, Mensud, Mohan, Viswanathan, Horowitz, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600123/
https://www.ncbi.nlm.nih.gov/pubmed/28303626
http://dx.doi.org/10.1002/dmrr.2897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600123/
https://www.ncbi.nlm.nih.gov/pubmed/28303626
http://dx.doi.org/10.1002/dmrr.2897

Ejemplares similares